Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Conditions

Subcategories:Axial SpondyloarthritisClinical Criteria/GuidelinesGout and Crystalline ArthritisMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis

Existing CT Scans as Good as DXA for Assessing Hip Fracture Risk

Scott Baltic  |  May 8, 2018

NEW YORK (Reuters Health)—A “biomechanical” analysis of a previously taken pelvic or abdominal computed tomography (CT) scan is at least as accurate in assessing an individual’s hip fracture risk as a dual-energy X-ray absorptiometry (DXA) scan, according to new research. This accuracy of the hip bone mineral density (BMD) T-score as measured by the biomechanical…

Gut Microbiota Directly Affects Inflammatory Arthritis

Lara C. Pullen, PhD  |  May 8, 2018

Gut microbiota may provide insight into important environmental triggers for autoimmune diseases. New research in mice indicates that intestinal dysbiosis triggers a mucosal immune response that stimulates T and B cells, which are critical to the development of inflammatory arthritis…

Diclofenac May Boost MI Risk in Patients with Spondyloarthritis

Marilynn Larkin  |  May 7, 2018

NEW YORK (Reuters Health)—Risk of myocardial infarction (MI) is increased in patients with spondyloarthritis (SpA) who use the nonsteroidal anti-inflammatory drug (NSAID) diclofenac, but not in those who take naproxen, researchers say. Maureen Dubreuil, MD, MSc, of Boston University School of Medicine, and colleagues analyzed 20 years of medical records from the U.K.’s Health Improvement…

RA Patients May Not Receive Needed Osteoporosis Screening & Treatment

Arthritis Care & Research  |  May 4, 2018

New research examined the frequency of osteoporosis screening and treatment for RA patients from 2003–2014, including four years following the release of the 2010 ACR guideline on glucocorticoid-induced osteoporosis prevention and treatment. The results: Approximately half of RA patients for whom treatment was indicated never received osteoporosis medication. Researchers also found that RA patients, despite their increased risk for developing osteoporosis, were not more likely to receive osteoporosis care than OA patients…

Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes

Reuters Staff  |  May 1, 2018

NEW YORK (Reuters Health)—Subcutaneous belimumab improves outcomes in anti-dsDNA-positive hypocomplementemic patients with systemic lupus erythematosus (SLE), according to results from a Phase 3 randomized, controlled trial. Intravenous belimumab is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of patients with active, autoantibody-positive SLE who are receiving standard…

Obesity Linked with Disability in RA

Lisa Rapaport  |  May 1, 2018

(Reuters Health)—Patients with rheumatoid arthritis (RA) may be more likely to become disabled if they’re obese, a U.S. study suggests. Researchers examined data on more than 25,000 patients with RA. Most were overweight or obese when they joined the study. Those who were severely obese were more likely to report some disability at baseline. Over…

International Approvals for Guselkumab & Anakinra; Plus Adalimumab Biosimilar in Europe

Michele B. Kaufman, PharmD, BCGP  |  April 30, 2018

In Japan the use of guselkumab to treat erythrodermic, plaque and pustular psoriasis is approved, and anakinra is now indicated for Still’s disease in the E.U…

New Study Raises Cardiovascular Questions about Febuxostat for Gout

Lara C. Pullen, PhD  |  April 30, 2018

New research raises questions about the cardiovascular safety of febuxostat for gout patients compared with allopurinol. The study found that although febuxostat was noninferior to allopurinol, febuxostat-treated patients had similar overall rates of major adverse cardiovascular events as allopurinol-treated patients, but had higher rates of all-cause mortality and cardiovascular mortality…

Clinical Remission Should Be Target of JIA Treatment: Task Force

Reuters Staff  |  April 27, 2018

NEW YORK (Reuters Health)—An international task force says patients with juvenile idiopathic arthritis (JIA) should be treated to a target of clinical remission, among other new recommendations. “The Task Force is convinced that transferring (the recommendations) into clinical practice will significantly improve the outcomes in patients with JIA,” Dr. Angelo Ravelli of the Istituto G….

New Arthritis Estimates Put Prevalence Numbers Much Higher Than Previously Thought

Catherine Kolonko  |  April 26, 2018

  Arthritis is often associated with retirees, but a new analysis of government data suggests the disease is much more common in young and middle-aged adults than previously believed. Disease prevalence is currently estimated at about 54 million adults, but that number is greatly underestimated, especially among those 64 and younger, according to a study…

  • « Previous Page
  • 1
  • …
  • 158
  • 159
  • 160
  • 161
  • 162
  • …
  • 342
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences